Antimüllerian hormone is reduced in the presence of ovarian endometriomas: a systematic review and meta-analysis

Muzii L, Ludovico Muzii, Chiara Di Tucci, Di Feliciantonio M, Mara Di Feliciantonio, Galati G, Giulia Galati, Violante Di Donato, Angela Musella, Innocenza Palaia, Palaia I, Panici PB, Pierluigi Benedetti Panici
Fertility and sterility · 2018 · vol. 110(5) , pp. 932–940.e1 · doi:10.1016/j.fertnstert.2018.06.025 · PMID:30316440 · W2896685552
Systematic review / meta-analysis OA: closed CC0 ⤵ 121 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This systematic review and meta-analysis found that antimüllerian hormone levels are significantly reduced in women with ovarian endometriomas compared to those without.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To evaluate if the presence of endometriomas impacts on the ovarian reserve as evaluated with antimüllerian hormone (AMH). DESIGN: Systematic review and meta-analysis. SETTING: Not applicable. PATIENT(S): Patients with unoperated endometriomas versus controls without endometriomas. INTERVENTION(S): Electronic databases searched up to June 2017 to identify articles evaluating AMH levels in patients with unoperated endometriomas versus controls without endometriomas. MAIN OUTCOME MEASURE(S): The primary analysis was aimed at evaluation of AMH levels (mean and SD) in patients with and without endometriomas. Secondary analyses were aimed at evaluating AMH levels in patients with ovarian endometriomas compared to patients with either non-endometriosis benign ovarian cysts or healthy ovaries. RESULT(S): Of the 39 studies evaluated in detail, 17 were included, for a total of 968 patients with endometriomas and 1874 without endometriomas. AMH was significantly lower in patients with unoperated endometriomas compared to patients with no endometriomas (mean difference -0.84, with 95% confidence interval [CI] -1.16 to -0.52). At secondary analyses, AMH in patients with endometriomas was significantly lower both versus non-endometriosis benign ovarian cysts (mean difference -0.85, 95% CI -1.37 to -0.32, and versus women with healthy ovaries (mean difference -0.61, 95% CI -0.99 to -0.24). CONCLUSION(S): Ovarian reserve evaluated with AMH is reduced in patients with ovarian endometriomas compared both to patients with other benign ovarian cysts, and to patients with healthy ovaries.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Anti-Mullerian Hormone Endometriosis Ovarian Cysts Ovarian Reserve Anti-Mullerian Hormone Anti-Mullerian Hormone Biomarkers Biomarkers Biomarkers Endometriosis Endometriosis Endometriosis Endometriosis Female Female Humans Humans Ovarian Cysts Ovarian Cysts Ovarian Cysts

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (65)

Cited by (50)

Source provenance

europepmc
last seen: 2026-10-16T06:09:50.462052+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:23:08.188623+00:00
unpaywall
last seen: 2026-09-17T06:32:46.214484+00:00
License: CC0 · commercial use OK